Significant association of increased PD-L1 and PD-1 expression with nodal metastasis and a poor prognosis in oral squamous cell carcinoma

Yasuyuki Maruse, Shintarou Kawano, Teppei Jinno, Ryota Matsubara, Y. Goto, N. Kaneko, T. Sakamoto, Y. Hashiguchi, Masafumi Moriyama, T. Toyoshima, ryoji kitamura, H. Tanaka, Kazunari Oobu, Tamotsu Kiyoshima, Seiji Nakamura

研究成果: ジャーナルへの寄稿記事

15 引用 (Scopus)

抄録

Programmed cell death ligand 1 (PD-L1) and its receptor PD-1 are immune checkpoint molecules that attenuate the immune response. Blockade of PD-L1 enhances the immune response in a variety of tumours and thus serves as an effective anti-cancer treatment. However, the biological and prognostic roles of PD-L1/PD-1 signalling in oral squamous cell carcinoma (OSCC) remain to be elucidated. The purpose of this study was to examine the correlation of PD-L1/PD-1 signalling with the prognosis of OSCC patients to assess its potential therapeutic relevance. The expression of PD-L1 and of PD-1 was determined immunohistochemically in 97 patients with OSCC and the association of this expression with clinicopathological characteristics was examined. Increased expression of PD-L1 was found in 64.9% of OSCC cases and increased expression of PD-1 was found in 61.9%. Univariate and multivariate analysis revealed that increased expression of PD-L1 and PD-1 positively correlated with cervical lymph node metastasis. The expression of CD25, an activated T-cell marker, was negatively correlated with the labelling index of PD-L1 and PD-1. Moreover, the patient group with PD-L1-positive and PD-1-positive expression showed a more unfavourable prognosis than the group with PD-L1-negative and PD-1-negative expression. These data suggest that increased PD-L1 and PD-1 expression is predictive of nodal metastasis and a poor prognosis and is possibly involved in cancer progression via attenuating the immune response.

元の言語英語
ページ(範囲)836-845
ページ数10
ジャーナルInternational Journal of Oral and Maxillofacial Surgery
47
発行部数7
DOI
出版物ステータス出版済み - 7 1 2018

Fingerprint

CD274 Antigen
Squamous Cell Carcinoma
Neoplasm Metastasis
Cell Death
Ligands
Programmed Cell Death 1 Receptor
Neoplasms
Multivariate Analysis
Lymph Nodes
T-Lymphocytes

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oral Surgery
  • Otorhinolaryngology

これを引用

@article{c7f98f426ac3479895379e1640116d52,
title = "Significant association of increased PD-L1 and PD-1 expression with nodal metastasis and a poor prognosis in oral squamous cell carcinoma",
abstract = "Programmed cell death ligand 1 (PD-L1) and its receptor PD-1 are immune checkpoint molecules that attenuate the immune response. Blockade of PD-L1 enhances the immune response in a variety of tumours and thus serves as an effective anti-cancer treatment. However, the biological and prognostic roles of PD-L1/PD-1 signalling in oral squamous cell carcinoma (OSCC) remain to be elucidated. The purpose of this study was to examine the correlation of PD-L1/PD-1 signalling with the prognosis of OSCC patients to assess its potential therapeutic relevance. The expression of PD-L1 and of PD-1 was determined immunohistochemically in 97 patients with OSCC and the association of this expression with clinicopathological characteristics was examined. Increased expression of PD-L1 was found in 64.9{\%} of OSCC cases and increased expression of PD-1 was found in 61.9{\%}. Univariate and multivariate analysis revealed that increased expression of PD-L1 and PD-1 positively correlated with cervical lymph node metastasis. The expression of CD25, an activated T-cell marker, was negatively correlated with the labelling index of PD-L1 and PD-1. Moreover, the patient group with PD-L1-positive and PD-1-positive expression showed a more unfavourable prognosis than the group with PD-L1-negative and PD-1-negative expression. These data suggest that increased PD-L1 and PD-1 expression is predictive of nodal metastasis and a poor prognosis and is possibly involved in cancer progression via attenuating the immune response.",
author = "Yasuyuki Maruse and Shintarou Kawano and Teppei Jinno and Ryota Matsubara and Y. Goto and N. Kaneko and T. Sakamoto and Y. Hashiguchi and Masafumi Moriyama and T. Toyoshima and ryoji kitamura and H. Tanaka and Kazunari Oobu and Tamotsu Kiyoshima and Seiji Nakamura",
year = "2018",
month = "7",
day = "1",
doi = "10.1016/j.ijom.2018.01.004",
language = "English",
volume = "47",
pages = "836--845",
journal = "International Journal of Oral and Maxillofacial Surgery",
issn = "0901-5027",
publisher = "Churchill Livingstone",
number = "7",

}

TY - JOUR

T1 - Significant association of increased PD-L1 and PD-1 expression with nodal metastasis and a poor prognosis in oral squamous cell carcinoma

AU - Maruse, Yasuyuki

AU - Kawano, Shintarou

AU - Jinno, Teppei

AU - Matsubara, Ryota

AU - Goto, Y.

AU - Kaneko, N.

AU - Sakamoto, T.

AU - Hashiguchi, Y.

AU - Moriyama, Masafumi

AU - Toyoshima, T.

AU - kitamura, ryoji

AU - Tanaka, H.

AU - Oobu, Kazunari

AU - Kiyoshima, Tamotsu

AU - Nakamura, Seiji

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Programmed cell death ligand 1 (PD-L1) and its receptor PD-1 are immune checkpoint molecules that attenuate the immune response. Blockade of PD-L1 enhances the immune response in a variety of tumours and thus serves as an effective anti-cancer treatment. However, the biological and prognostic roles of PD-L1/PD-1 signalling in oral squamous cell carcinoma (OSCC) remain to be elucidated. The purpose of this study was to examine the correlation of PD-L1/PD-1 signalling with the prognosis of OSCC patients to assess its potential therapeutic relevance. The expression of PD-L1 and of PD-1 was determined immunohistochemically in 97 patients with OSCC and the association of this expression with clinicopathological characteristics was examined. Increased expression of PD-L1 was found in 64.9% of OSCC cases and increased expression of PD-1 was found in 61.9%. Univariate and multivariate analysis revealed that increased expression of PD-L1 and PD-1 positively correlated with cervical lymph node metastasis. The expression of CD25, an activated T-cell marker, was negatively correlated with the labelling index of PD-L1 and PD-1. Moreover, the patient group with PD-L1-positive and PD-1-positive expression showed a more unfavourable prognosis than the group with PD-L1-negative and PD-1-negative expression. These data suggest that increased PD-L1 and PD-1 expression is predictive of nodal metastasis and a poor prognosis and is possibly involved in cancer progression via attenuating the immune response.

AB - Programmed cell death ligand 1 (PD-L1) and its receptor PD-1 are immune checkpoint molecules that attenuate the immune response. Blockade of PD-L1 enhances the immune response in a variety of tumours and thus serves as an effective anti-cancer treatment. However, the biological and prognostic roles of PD-L1/PD-1 signalling in oral squamous cell carcinoma (OSCC) remain to be elucidated. The purpose of this study was to examine the correlation of PD-L1/PD-1 signalling with the prognosis of OSCC patients to assess its potential therapeutic relevance. The expression of PD-L1 and of PD-1 was determined immunohistochemically in 97 patients with OSCC and the association of this expression with clinicopathological characteristics was examined. Increased expression of PD-L1 was found in 64.9% of OSCC cases and increased expression of PD-1 was found in 61.9%. Univariate and multivariate analysis revealed that increased expression of PD-L1 and PD-1 positively correlated with cervical lymph node metastasis. The expression of CD25, an activated T-cell marker, was negatively correlated with the labelling index of PD-L1 and PD-1. Moreover, the patient group with PD-L1-positive and PD-1-positive expression showed a more unfavourable prognosis than the group with PD-L1-negative and PD-1-negative expression. These data suggest that increased PD-L1 and PD-1 expression is predictive of nodal metastasis and a poor prognosis and is possibly involved in cancer progression via attenuating the immune response.

UR - http://www.scopus.com/inward/record.url?scp=85040971044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040971044&partnerID=8YFLogxK

U2 - 10.1016/j.ijom.2018.01.004

DO - 10.1016/j.ijom.2018.01.004

M3 - Article

VL - 47

SP - 836

EP - 845

JO - International Journal of Oral and Maxillofacial Surgery

JF - International Journal of Oral and Maxillofacial Surgery

SN - 0901-5027

IS - 7

ER -